Cybin (CYBN, Financial) has successfully obtained a U.S. patent numbered 12,291,499 from the United States Patent and Trademark Office for its CYB003 program, targeting major depressive disorder (MDD). This patent is poised to grant the company exclusive rights until 2041, covering specific pharmaceutical compositions and oral dosage forms of their innovative deuterated psilocin analog, CYB003.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 4 analysts, the average target price for Cybin Inc (CYBN, Financial) is $70.92 with a high estimate of $150.36 and a low estimate of $25.06. The average target implies an upside of 1,042.02% from the current price of $6.21. More detailed estimate data can be found on the Cybin Inc (CYBN) Forecast page.
Based on the consensus recommendation from 6 brokerage firms, Cybin Inc's (CYBN, Financial) average brokerage recommendation is currently 1.8, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
